company background image
CBIO

Catalyst Biosciences NasdaqCM:CBIO Stock Report

Last Price

US$0.28

Market Cap

US$10.6m

7D

-5.1%

1Y

-53.4%

Updated

31 Jan, 2023

Data

Company Financials +

Catalyst Biosciences, Inc.

NasdaqCM:CBIO Stock Report

Mkt Cap: US$10.6m

CBIO Stock Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation.

CBIO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Catalyst Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Biosciences
Historical stock prices
Current Share PriceUS$0.28
52 Week HighUS$2.09
52 Week LowUS$0.20
Beta1.38
1 Month Change-46.54%
3 Month Change-49.28%
1 Year Change-53.42%
3 Year Change-96.24%
5 Year Change-98.93%
Change since IPO-99.79%

Recent News & Updates

Recent updates

Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky

Jan 11
Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky

Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why

Jun 03
Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why

Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely

May 18
Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely

Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?

Mar 09
Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?

We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely

Feb 01
We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely

Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?

Dec 28
Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?

What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay

Dec 02
What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay

Shareholder Returns

CBIOUS BiotechsUS Market
7D-5.1%-1.4%0.2%
1Y-53.4%1.2%-13.6%

Return vs Industry: CBIO underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: CBIO underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is CBIO's price volatile compared to industry and market?
CBIO volatility
CBIO Average Weekly Movement18.0%
Biotechs Industry Average Movement12.3%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: CBIO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: CBIO's weekly volatility has decreased from 37% to 18% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200245Nassim Usmanhttps://www.catalystbiosciences.com

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company’s protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD.

Catalyst Biosciences, Inc. Fundamentals Summary

How do Catalyst Biosciences's earnings and revenue compare to its market cap?
CBIO fundamental statistics
Market CapUS$10.65m
Earnings (TTM)US$11.88m
Revenue (TTM)US$3.23m

0.9x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CBIO income statement (TTM)
RevenueUS$3.23m
Cost of RevenueUS$27.14m
Gross Profit-US$23.90m
Other Expenses-US$35.79m
EarningsUS$11.88m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.31
Gross Margin-739.18%
Net Profit Margin367.44%
Debt/Equity Ratio0%

How did CBIO perform over the long term?

See historical performance and comparison